- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07714200
Abstinence Reinforcement Therapy for Veterans Who Smoke Tobacco and Are Experiencing Homelessness (New HART)
15 juli 2026 uppdaterad av: VA Office of Research and Development
Seventy to eighty percent of Veterans experiencing homelessness (VEH) smoke, which is four times the rate of the U.S. population and 2.5 times higher than among impoverished Americans.
Smoking- related deaths among persons experiencing homelessness occur at double the rate seen among more stably housed people.
The purpose of this study study is to evaluate the effectiveness of an intervention to help Veterans experiencing homelessness stop smoking.
The intervention, called Abstinence Reinforcement Therapy + (ART+), includes telehealth-based counseling, smoking cessation aids, and mobile contingency management (mCM).
mCM is an intervention in which participants are paid for smoking abstinence.
120 Veterans who smoke cigarettes and are experiencing homelessness will be randomly assigned to receive either ART+ or usual smoking cessation care.
The primary outcome to be evaluated is the rate at which Veterans assigned to the ART+ condition report smoking abstinence and have their abstinence verified using salivary testing.
Studieöversikt
Status
Har inte rekryterat ännu
Betingelser
Detaljerad beskrivning
Significance to VA: Seventy to eighty percent of Veterans experiencing homelessness (VEH) smoke, which is four times the rate of the U.S. population and 2.5 times higher than among impoverished Americans.
Smoking- related deaths among persons experiencing homelessness occur at double the rate seen among more stably housed people.
While there are numerous challenges to smoking cessation among Veterans experiencing homelessness, four in five homeless smokers report interest in quitting.
Innovation and Impact: The investigators recently developed and evaluated the effectiveness of a multi-component intervention called Abstinence Reinforcement Therapy (ART), which combined five sessions of telehealth-based cognitive-behavioral therapy, provision of smoking cessation aids, and four weeks of mobile contingency management (mCM).
The investigators have added an additional CM period of eight weeks and opportunities for booster calls and repeated quit attempts, resulting in an intervention called ART+ to improve outcomes over time.
The innovative use of web-based platform technology in the current proposal will remove numerous barriers that often prevent smokers experiencing homelessness from accessing high-quality, evidence-based care.
There is tremendous inequity in smoking-related outcomes for VEH.
The innovative use of mobile health technology in the current proposal will remove numerous barriers that often prevent Veterans who smoke and experience homelessness from accessing high- quality, evidence-based care.
Specific Aims: Aim 1: Evaluate the comparative effectiveness of ART+ on bio-verified abstinence outcomes at three-, six-and 12-month follow-ups.
The primary endpoint will be bioverified prolonged abstinence at the six-month follow-up.
Aim 2: Assess the relative cost-effectiveness of ART+ to VA standard care smoking cessation on quality adjusted life years (QALY).
Aim 3: Qualitatively evaluate implementation determinants of ART+ within Specialty Smoking Clinics and VA primary care for VEH programs.
Methodology: 120 Veterans experiencing homelessness who smoke cigarettes will be randomly assigned to ART+ or to VA standard smoking cessation care.
Self-reported and bioverified abstinence at six months are the primary outcomes.
Cost-effectiveness analyses will be performed using QALY as the effectiveness measure.
Rapid qualitative analytic methods will be used to evaluate implementation determinants of ART+ following enrollment of all study participants.
Participants for the qualitative analysis will include clinicians and clinical support staff who provide care to Veterans experiencing homelessness, designated VA operations partners, and VA Tobacco Treatment Specialists.
Purposive sampling will be used to identify potential participants and a structured interview guide based upon domains from the Consolidated Framework for Implementation Research (CFIR) will be administered.
The investigators will use rapid qualitative analysis to answer the key qualitative research question: "What determinants will impact implementation of ART+?"
The benefit of decreasing tobacco use (Aim 1) among VEH who smoke is tremendous as it will prevent significant morbidity and mortality.
Moreover, if ART+ is shown to be cost effective (Aim 2) and implementation determinants are identified (Aim 3), the use of mobile phones as a platform to provide behavioral incentives has the potential to transform the delivery of smoking cessation care.
Path to Translation/Implementation: Cost-effectiveness analysis (Aim 2) will help guide implementation decisions.
Qualitative evaluation of the implementation determinants of ART+ within Specialty Smoking Clinics and VA primary care for VEH programs (Aim 3) will provide important information on effective implementation of ART+.
Studietyp
Interventionell
Inskrivning (Beräknad)
120
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Angela C Kirby, MS
- Telefonnummer: 7456 (919) 286-0411
- E-post: angela.kirby@va.gov
Studieorter
-
-
North Carolina
-
Durham, North Carolina, Förenta staterna, 27705-3875
- Durham VA Medical Center, Durham, NC
-
Kontakt:
- Angela C Kirby, MS
- Telefonnummer: 7456 919-286-0411
- E-post: angela.kirby@va.gov
-
Huvudutredare:
- Jean C Beckham, PhD
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Are homeless
- Smoke at least 5 cigarettes daily with CO indicating current smoking at time of screening assessment
- Are willing to try to quit smoking in next 30 days
Exclusion Criteria:
- Have uncontrolled psychotic symptoms
- Have active substance dependence other than nicotine (participants in partial remission with at least one month sobriety will be included)
- Have severely impaired hearing or speech
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Abstinence Reinforcement Therapy +
Abstinence Reinforcement Therapy +, or ART+, includes five sessions and several booster sessions of cognitive-behavioral therapy for smoking cessation, two forms of nicotine replacement therapy plus bupropion or varenicline, and mobile contingency management for smoking cessation.
|
Five core sessions of CBT plus up to four monthly booster sessions designed to help Veterans prepare to quit smoking, make a quit attempt, and prevent relapse to smoking.
Andra namn:
NRT is a group of over-the-counter medications designed to help users quit smoking.
Standard of care often involves use of nicotine patch plus one rescue method (either gum or lozenge).
Andra namn:
Bupropion is an FDA-approved prescription smoking cessation aid.
Participants will be prescribed 150-300 mg.
Andra namn:
Varenicline is an FDA-approved prescription smoking cessation aid.
Participants will be 0.5 to 2 mg.
Andra namn:
Smoking abstinence will be intermittently reinforced.
For each carbon monoxide (CO) reading that a participant provides that suggest smoking abstinence, the participant will earn spins on a virtual prize wheel that has financial prizes.
Andra namn:
|
|
Aktiv komparator: Standard Care Condition
Standard Care Condition will involve referral to local VA clinic-based smoking cessation care.
This care often includes pharmacotherapy, counseling options, and/or use of a telephone-based, texting-based or app-based smoking cessation program.
|
NRT is a group of over-the-counter medications designed to help users quit smoking.
Standard of care often involves use of nicotine patch plus one rescue method (either gum or lozenge).
Andra namn:
Bupropion is an FDA-approved prescription smoking cessation aid.
Participants will be prescribed 150-300 mg.
Andra namn:
Varenicline is an FDA-approved prescription smoking cessation aid.
Participants will be 0.5 to 2 mg.
Andra namn:
Participants assigned to the usual care condition may participate in group counseling for smoking cessation, which can also include use of phone-based smoking cessation resources such as a telephone quit line, a texting program, and a smoking cessation app.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of participants whose self-report of prolonged smoking abstinence is bioverified
Tidsram: 6-month follow-up, about six months after baseline
|
Prolonged abstinence is defined as 30 days abstinent.
For participants who are not using NRT/vapes/e-cigarettes at follow-up, abstinence will be based upon: 1) self-reported abstinence; 2) no biochemical samples indicating smoking (CO ≥ 5 ppm or cotinine ≥ 6 ng/mL); and 3) at least one sample indicating abstinence (CO < 5 ppm and/or cotinine < 6 ng/mL)
|
6-month follow-up, about six months after baseline
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of participants whose self-report of prolonged smoking abstinence is bioverified
Tidsram: 3-month follow-up, about three months after baseline
|
Prolonged abstinence is defined as 30 days abstinent.
For participants who are not using NRT/vapes/e-cigarettes at follow-up, abstinence will be based upon: 1) self-reported abstinence; 2) no biochemical samples indicating smoking (CO ≥ 5 ppm or cotinine ≥ 6 ng/mL); and 3) at least one sample indicating abstinence (CO < 5 ppm and/or cotinine < 6 ng/mL)
|
3-month follow-up, about three months after baseline
|
|
Number of participants whose self-report of prolonged smoking abstinence is bioverified
Tidsram: 12-month follow-up, about twelve months after baseline
|
Prolonged abstinence is defined as 30 days abstinent.
For participants who are not using NRT/vapes/e-cigarettes at follow-up, abstinence will be based upon: 1) self-reported abstinence; 2) no biochemical samples indicating smoking (CO ≥ 5 ppm or cotinine ≥ 6 ng/mL); and 3) at least one sample indicating abstinence (CO < 5 ppm and/or cotinine < 6 ng/mL
|
12-month follow-up, about twelve months after baseline
|
|
Number of participants who self-report 7-day point prevalence abstinence
Tidsram: 3-month follow-up, about three months after baseline
|
7-day point prevalence abstinence is defined as no smoking in the prior 7 days
|
3-month follow-up, about three months after baseline
|
|
Number of participants who self-report 7-day point prevalence abstinence
Tidsram: 6-month follow-up, about six months after baseline
|
7-day point prevalence abstinence is defined as no smoking in the prior 7 days
|
6-month follow-up, about six months after baseline
|
|
Number of participants who self-report 7-day point prevalence abstinence
Tidsram: 12-month follow-up, about twelve months after baseline
|
7-day point prevalence abstinence is defined as no smoking in the prior 7 days
|
12-month follow-up, about twelve months after baseline
|
|
Number of participants who self-report 30-day point prevalence abstinence
Tidsram: 3-month follow-up, about three months after baseline
|
7-day point prevalence abstinence is defined as no smoking in the prior 30 days
|
3-month follow-up, about three months after baseline
|
|
Number of participants who self-report 30-day point prevalence abstinence
Tidsram: 6-month follow-up, about six months after baseline
|
7-day point prevalence abstinence is defined as no smoking in the prior 30 days
|
6-month follow-up, about six months after baseline
|
|
Number of participants who self-report 30-day point prevalence abstinence
Tidsram: 12-month follow-up, about twelve months after baseline
|
30-day point prevalence abstinence is defined as no smoking in the prior 30 days
|
12-month follow-up, about twelve months after baseline
|
|
Number of participants who self-report early continuous abstinence
Tidsram: 3-month follow-up, about three months after baseline
|
Early continuous abstinence will be defined as reporting two weeks of continuous abstinence during the first four weeks after the quit day
|
3-month follow-up, about three months after baseline
|
|
Incremental Cost-Effectiveness Ratio
Tidsram: 12 months post quit, about 12 months after baseline
|
Measure of cost-effectiveness; costs as the numerator and effectiveness as measured by quality-adjusted life years (QALY) as the denominator.
|
12 months post quit, about 12 months after baseline
|
|
Percentage of carbon monoxide reading completion by participants in ART+ intervention group
Tidsram: 3-month follow-up, about three months after baseline
|
Patient intervention utilization will be measured by the percentage of prompted carbon monoxide readings that participants in the ART+ condition complete during the treatment period.
|
3-month follow-up, about three months after baseline
|
|
Number of behavioral cognitive-behavioral therapy (CBT) sessions completed by participants in ART+ intervention group
Tidsram: 3-month follow-up, about three months after baseline
|
Patient intervention utilization will be measured by the number of behavioral cognitive-behavioral therapy (CBT) sessions completed by participants in the ART+ condition during the treatment period
|
3-month follow-up, about three months after baseline
|
|
Number of participants in ART+ intervention group who withdraw or are lost to contact during the treatment period
Tidsram: 3-month follow-up, about three months after baseline
|
Patient intervention utilization will be measured by the number of participants in ART+ intervention group who withdraw or are lost to contact during the treatment period.
|
3-month follow-up, about three months after baseline
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Utredare
- Huvudutredare: Jean C Beckham, PhD, Durham VA Medical Center, Durham, NC
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
1 mars 2027
Primärt slutförande (Beräknad)
1 mars 2030
Avslutad studie (Beräknad)
1 september 2030
Studieregistreringsdatum
Först inskickad
15 juli 2026
Först inskickad som uppfyllde QC-kriterierna
15 juli 2026
Första postat (Faktisk)
20 juli 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
20 juli 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
15 juli 2026
Senast verifierad
1 juli 2026
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Mentala störningar
- Substansrelaterade störningar
- Kemiskt inducerade störningar
- Beteende
- Störning av tobaksbruk
- Rökning
- Organiska kemikalier
- Pyridiner
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Terapeutik
- Narkotikabehandling
- Mat
- Diet, mat och näring
- Fysiologiska fenomen
- Mat och dryck
- Kolhydrater
- Alkaloider
- Beteendebehandling
- Psykoterapi
- Beteendediscipliner och aktiviteter
- Polymerer
- Makromolekylära ämnen
- Polysackarider
- Benzazepiner
- Ketoner
- Biopolymerer
- Kinoxaliner
- Gummis
- Godis
- Solanhaltiga alkaloider
- Tuggummi
- Propiofenoner
- Vareniklin
- Nikotin
- Bupropion
- Kognitiv beteendeterapi
- Tobak använder upphörande enheter
- Nikotinersättningsterapi
- Nikotin tuggummi
Andra studie-ID-nummer
- HSR2-003-25M
- 1924743 (Annan identifierare: Durham VA Medical Center IRB)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
produkt tillverkad i och exporterad från U.S.A.
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .